Lung Cancer |

Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA) for Staging Non-Small Cell Lung Cancer (NSCLC) in Patients Evaluated for Stereotactic Body Radiation Therapy (SBRT) FREE TO VIEW

Macarena Rodriguez Vial, MD
Author and Funding Information

MD Anderson Cancer Center, Houston, TX

Chest. 2015;148(4_MeetingAbstracts):546A. doi:10.1378/chest.2270311
Text Size: A A A
Published online


SESSION TITLE: Lung Cancer Diagnosis

SESSION TYPE: Original Investigation Slide

PRESENTED ON: Wednesday, October 28, 2015 at 02:45 PM - 04:15 PM

PURPOSE: Patients with NSCLC being evaluated for SBRT are typically staged non-invasively with PET/CT. Some centers have incorporated minimally invasive mediastinal staging with EBUS-TBNA as part of the standard workup due to its superior diagnostic accuracy for assessing nodal disease in patients with radiographic evidence of nodal disease. The additive benefit of EBUS-TBNA to non-invasive staging methods has not been evaluated in this particular setting. Our objective was to assess the change in nodal stage after EBUS-TBNA, when compared to clinico-radiological staging in this population.

METHODS: We reviewed the medical records of patients undergoing EBUS-TBNA for staging of NSCLC at MDACC from 2007-2013 and identified all subjects potentially eligible for SBRT, defined as i) primary tumor measuring ≤ 5 cm, and ii) N0M0 or N1M0 disease according to PET/CT. All patients were analyzed, regardless of the final treatment received. Our main outcome was the change in the N designation between PET/CT and EBUS-TBNA

RESULTS: From a total of 4,198 patient records, we identified a total of 266 eligible patients, 127 (49%) were female and majority were Caucasian (86%). Mean age was 69 (44-89). The main histological diagnoses were adenocarcinoma 51%, squamous 38%, and others 11%. Mean tumor size was 2.7 cm (0.7-5 cm), and most (76%) were peripherally located. Compared with radiographic staging, EBUS-TBNA led to stage shift in 47 out of 266 patients (18%). Out of 190 clinical N0 patients, 7 (3.7%) were found to have occult nodal disease on EBUS-TBNA. Of them, 5 were upstaged to N1 and 2 to N2. Of note, occult disease was only found in patients with tumors > 2 cm (T1B or higher). Among the 74 patients with N1 disease, 40 (54%) were downstaged to N0 after EBUS-TBNA, and therefore became SBRT eligible.

CONCLUSIONS: Incorporating EBUS-TBNA in the staging work up resulted in a change in the N designator in a substantial fraction of radiographically early stage NSCLC patients.

CLINICAL IMPLICATIONS: EBUS-TBNA was beneficial in both identifying occult nodal disease that would otherwise be left untreated with SBRT, and in expanding the pool of patients eligible for SBRT who would otherwise not have been candidates based on non-invasive staging.

DISCLOSURE: The following authors have nothing to disclose: Macarena Rodriguez Vial

No Product/Research Disclosure Information




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543